Skip to main content

Table 2 Outcomes at 12 months in the entire cohort, naïve and non-naïve patients, by ART regimen

From: Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America

 

All

ART naïve

ART non-naïve

Efavirenz (n = 647)

non Efavirenz (n = 318)

Efavirenz (n = 420)

non Efavirenz (n = 98)

Efavirenz (n = 227)

non Efavirenz (n = 220)

Death

84 (13%)

29 (9%)

51 (12%)

10 (10%)

33 (14%)

19 (9%)

LTFU

129 (20%)

50 (16%)

100 (24%)

20 (20%)

29 (13%)

30 (14%)

Undetectable HIV-RNA

220 (34%)

132 (41%)

134 (32%)

35 (36%)

86 (38%)

97 (44%)

Detectable HIV-RNA

67 (11%)

34 (11%)

44 (10%)

8 (8%)

23 (10%)

26 (12%)

Active no VL

147 (23%)

73 (23%)

91 (22%)

25 (25%)

56 (25%)

48 (22%)

p value

0.08

0.78

0.27

  1. Note: p values reflect the comparison of the overall distribution of outcomes for efavirenz- and non-efavirenz containing ART regimens
  2. LTFU lost to follow-up, HIV-RNA Undetectable VL < 400 at 12 months, VL viral load
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us